• Rate futures put December FOMC hike odds near 90%, with a 50 basis point move priced at about 10%.
• Core CPI rose 0.3% for a third straight month, an annualized pace of 3.7%.
• Fed Chair Kevin Warsh opens an AI and inflation forum in San Francisco on November 16.
Rate Futures Price a Near-Certain December Hike
Rate futures opened the week with a near-certain hike priced in. The implied probability of a 25 basis point increase at the December FOMC meeting stood close to 90%, and a larger 50 basis point move carried roughly 10% odds. The repricing follows the core CPI report, which rose 0.3% for the third consecutive month, an annualized pace of 3.7% that has deepened concern that inflation is entrenched rather than fading. Fed Chair Kevin Warsh dominates the calendar from here. On November 16 he convenes a public forum in San Francisco, bringing together big tech executives and economists to debate whether artificial intelligence lowers prices or, through data-center power and infrastructure spending, drives them higher. The 10-year Treasury yield at 5.15% is the pressure point: a Warsh diagnosis that AI capital expenditure lengthens the cycle of inflation and high rates could push the yield up again, and the burden would fall on Nasdaq technology names. Crypto has already traded the higher-rate path first. Bitcoin rebounded from a Sunday low of $62,081 to trade between $64,594 and $64,994 on Monday, with volume up 58%, but flows through the spot Bitcoin ETF complex stayed defensive: outflows ran for a seventh consecutive session, and a firm footing above $65,000 is not secured. In support and resistance terms, the $62,081 Sunday low is the reference level beneath the market. Pressure also arrived outside the rate complex. President Donald Trump's hardline remarks on Mexico tariffs weighed on Dow futures, while the dollar's advance toward the 160 yen line kept Bank of Japan rate-hike bets alive.
NVIDIA's $109 Billion Test
NVIDIA is the week's second test, and the two events are linked. The data-center spending that Warsh's forum will weigh as an inflation driver is the same spending stream behind NVIDIA's revenue, so the earnings guide doubles as a macro reading. Shares had corrected more than 30% over the past month, and Yardeni Research puts the stock's 12-month forward price-to-earnings ratio at 11.5 times, a compressed starting point for the print. The company reports fiscal third-quarter results after the close on November 17. Consensus revenue sits at $108.8 billion to $109.1 billion, close to double the $57 billion recorded a year earlier. Options markets price a swing of plus or minus 10.6% in the share price around the release. Retail positioning is aggressive on the other side of the Pacific. Korea Securities Depository (SEIBRO) data shows about 6.6 trillion won poured into SOXL, the three-times leveraged semiconductor ETF, over the past month, and roughly 100 billion won of net NVIDIA buying between November 6 and 12. Brokerages flag the tension inside that bet. A forward multiple of 11.5 times looks attractive on its own, they note, but with December hike odds at 90% and event volatility embedded in the week, three-times leveraged products such as SOXL and TQQQ can erode principal quickly through negative compounding in sideways or short-pullback phases. The week then runs on a fixed script: Warsh's forum on November 16, NVIDIA's earnings on November 17, and the Nasdaq listing of Anthropic (ANT) on November 19.
Our reading: with a December hike close to fully priced, repricing risk has moved off the FOMC decision itself and onto the words around it. Warsh's framing of AI capital expenditure and NVIDIA's revenue guidance now carry more potential to move yields than the meeting does. The day's hardest hit sat in crypto, where the spot ETF wrapper absorbed the rate shock first: seven straight outflow days came before Monday's bounce, and Bitcoin's recovery to the $64,594 to $64,994 range leaves it roughly 4% above the $62,081 floor. That floor is now the level with the most weight. A Warsh speech that validates the high-for-longer diagnosis would put it straight back under test.
